MEI Pharma Inc Zandelisib Phase 2 TIDAL Study Data Webcast Transcript
Good morning, and welcome to the MEI Pharma Phase II TIDAL Study Data Announcement Webcast. (Operator Instructions) Please note, this event is being recorded. I would now like to turn the conference over to David Walsey, Senior Vice President. Please go ahead.
Thank you, Andrea. Thank you. On our video webcast today, we will review data from the Phase II TIDAL study evaluating our investigational drug candidate, zandelisib, announced earlier today. We will also review additional data and information related to the zandelisib program.
Before we get started, I want to call your attention to the fact that this conference call may contain certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in our forward-looking statements, which are based on management's current expectations and are subject to a number of risks and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
